Immunicom, Inc.

📍 San Diego, United States🗓 Founded 2013👥 22 employees💰 Last funded Jan 2020
Biotechnology🌐 immunicom.com
Website LinkedIn
Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients’ quality of life – all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicoms cancer therapy has the potential to allow the body’s natural immune system to directly attack the cancer while enhancing the effects of other cancer treatments which may be used concurrently. At Immunicom we are reimagine how healing should be.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Immunicom, Inc.?
Immunicom, Inc. has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Immunicom, Inc. last raise funding?
The most recent investment in Immunicom, Inc. recorded on gritt.io was in January 2020.
When was Immunicom, Inc. founded?
Immunicom, Inc. was founded in 2013.
What industry is Immunicom, Inc. in?
Immunicom, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Immunicom, Inc. based?
Immunicom, Inc. is headquartered in San Diego, United States.